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Dendritic Cell Activation in Allogeneic Haematopoietic
Cell Transplantation: A Promising Target for Diagnosis
and Therapy
Derek N.J. Hart 1, Nirupama D. Verma 1, Georgina J. Clark 1,
Phillip D. Fromm1, Kifah Shahin 1,2, Stephen Larsen 3,
Kenneth Bradstock 1,4. 1 Dendritic Cell Biology and Therapeutics
Group, ANZAC Research Institute, Sydney, Australia; 2 Flow
Cytometry Unit, Institute of Clinical Pathology and Medical
Research, and Medical Research, Institute of Clinical Pathology,
Westmead Hospital, Sydney, Australia; 3Haematology, Royal
Prince Alfred Hospital, Camperdown, Australia; 4 BMT Service,
Westmead Hospital, Sydney, Australia
Acute and chronic graft versus host disease (GVHD) are
major limiting factors for the success of allogeneic hemato-
poietic cell transplantation (alloHCT) as curative therapy for
haematological malignancies. Though the occurrence of
GVHD is controlled in part by non-speciﬁc T cell directed
immunosuppression, this contributes to disease relapse and
increased risk of infections. Dendritic cells (DC) direct
immune responses and reinforce regulatory mechanisms.
Targeting DC activation as a novel immunosuppressive
strategy may limit the generation of deleterious T cell
responses and preserve regulatory T cell responses, whilst
preserving T cell responses to leukemia and pathogens. We
have shown that presence of activated CMRF-44+CD11c+ DC
predicts for acute GVHD after clinical alloHCT (Trans-
plantation 2007;83:839). This may reﬂect systemic activation
of blood DC or their migration after activation. Our recent
data associating CCR5 expression on CD16+ DC with clinical
acute GVHD (submitted) supports the latter concept. Such
observations may enable earlier intervention with current
agents or potentially new mAb targeting activated DC. Mice
with human PBMC xenograft undergoing early graft versus
host disease events have CMRF-44+CD11c+ DC. We have
shown efﬁcacy of an anti-human CD83 antibody in pre-
venting xenogenic GVHD but preserving protective anti viral
and leukemic responses (J Exp Med 2009;206:387). Similar
efﬁcacy of anti CD83 antibody in mouse alloHCT was re-
ported recently (BMT 2011;46 Suppl:P837). Our ongoing
studies focus on human DC subpopulations in clinical
alloHCT. We have now identiﬁed activated CMRF-44+ DC in
chronic GVHD and shown that they decline with effective
extracorporeal photochemotherapy. This justiﬁes the
extended evaluation of new human anti CD83 mAb and new
CMRF-44 like mAb being developed in our laboratory as
potential new immunosuppressive agents. Current studies
conﬁrm their ability to inhibit human immune responses in
vitro and in vivo and we plan to test these new anti-DC
therapeutics in Phase 1 studies in alloHCT.
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Identiﬁcation and Typing of Killer-Cell Immunoglobulin-
Like Receptors (KIRs) Using Quantitative PCR Assay
Reagents for Research
Persis P. Wadia 1, Doug Bost 2. 1 Product Development, Quest
Diagnostics, Alameda, CA; 2 Celera, Alameda, CA
Aim: Recent publications demonstrate after an allogeneic
hematopoietic cell transplant (HCT), anti-leukemia effects
are primarily provided by Tcells and Natural Killer (NK) cells.
NK cells play a role in reduced graft versus host disease and
in increased graft versus leukemia effects predominantly due
to their cell surface receptors namely Killer-cell immuno-
globulin-like receptors (KIRs). Conventional KIR genotypingmethods involve sequence-speciﬁc primer (SSP)-PCR or
sequence speciﬁc oligonucleotide hybridization PCR fol-
lowed by visualization of PCR products by agarose gel elec-
trophoresis or using sequence-based typing. Lack of
a universal test to type KIR combined with the low
throughput and high costs of existing methodologies
prompted the development of a prototype quantitative PCR
(qPCR) assay for KIR genotyping. The prototype assay uses
ﬂuorescent hydrolysis probes and may provide accurate and
fast KIR genotyping with minimal DNA to aid in KIR geno-
typing for pre and post-transplantation research.
Methods: Panel of 24 DNA containing common KIR geno-
types was obtained from UCLA DNA exchange. 240 ng total
DNA for 16 KIR reactions (each reaction run in triplicate) was
used for the prototype qPCR assay and results were
compared with a PCR-SSP KIR genotyping kit utilizing 3 ug
total DNA. The prototype assay consists of reagents to
perform multiplexed KIR genotyping which is ampliﬁcation
of a KIR gene and an internal qPCR reference gene for
normalizations, quantiﬁcation, and conﬁrmation of true
absence of KIR genes.
Results: The prototype qPCR assay results were 100%
concordant with the commercial PCR-SSP kit. The qPCR assay
accurately detected each KIR gene with a 12 fold reduction in
the amount of DNA required. There was no-post PCR analysis
or additional specialized equipment with all KIR genes being
ampliﬁed under the same thermocycling conditions.
Conclusions: We have shown feasibility for a prototype
qPCR assay for KIR genotyping that is robust and ﬂexible for
both small and large scale genetic analysis studies. With
implications of KIR in transplantation (particularly in AML
HCT), autoimmune and infectious diseases, and pregnancy-
related complications, faster detection might aid earlier
therapy intervention and a more sensitive assay can poten-
tially identify previously unidentiﬁed novel associations.
Genotyping KIRs using qPCR based assays could be useful in
both clinical and basic research settings.406
Haploidentical Allogeneic Hematopoietic Stem Cell
Transplantation for the Treatment of Refractory/Relapsed
Acute Leukemia
Yu Wang, Dai-hong Liu, Kai-yan Liu, Lan-ping Xu,
Xiao-hui Zhang, Wei Han, Huan Chen, Yu-hong Chen,
Feng-rong Wang, Jing-zhi Wang, Hai-xia Fu, Xiao-jun Huang.
Institute of Hematology, Peking University People's Hospital,
Beijing, China
Objective: To retrospectively analyze the results of refrac-
tory/relapsed acute leukemia patients who received human
leukocyte antigen (HLA)-mismatched/haploidentical alloge-
neic hematopoietic stem cell transplantation (allo-HSCT) and
to perform risk factor analysis.
Methods: Of the 96 refractory/relapsed acute leukemia(AL)
patients, 56 patients suffered from acute myeloid leuke-
mia(AML) and 35 patients suffered from acute lymphoid
leukemia (ALL), all in non-remission(NR) or relapse before
transplant. Most patients received conditioning therapy
comprised of modiﬁed busulfan/cyclophosphamide (BuCy)
plus thymoglobulin (ATG).
Results: With a median follow-up of 373d(34-3157d), 33/
96(34%) survived, 31/96(32%) survived without leukemia,
35/96(36%) relapsed. The estimated 3-year overall survival
(OS) and disease-free survival (DFS) of the 96 cases was 30.2%
and 29.0%. The 3-year OS were signiﬁcantly higher for AML
patients (39.2%) than for ALL patients (15.4%) (P ¼ .005), the
OS probability of patients with prophylactic donor
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without prophylactic DLI (38.0% vs 11.8%,P¼0.001). Sex, age,
conditioning regimen (dosage of ATG), number of HLA mis-
matched or the number of stem cells infused were not the
factors affecting OS, DFS and relapse. Multivariate analysis
showed that the signiﬁcant factors associated with higher OS
were the use of prophylactic DLI, the disease type of AML and
occurrence of chronic GVHD.
Conclusions: Haploidentical allo-HSCT can cure a signiﬁcant
proportion of refractory/relapsed acute leukemia patients.
Prophylactic DLI can reduce relapse and increase survival; for
patients with refractory/relapsed ALL, other post-transplant
therapy should be explored.
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High Risk Allogeneic Hematopoietic Cell Transplant (HCT)
Patients with Any Level of Cytomegalovirus (CMV)
Viremia Should Be Treated with Antiviral Therapy to
Prevent Serious CMV Disease
Lena Winestone 1, Rajni Agarwal 2, Kenneth I. Weinberg 3,
Matthew Porteus 4, Jennifer Reikes Willert 5, Michael Amylon 6,
Sandhya Kharbanda 7. 1 Pediatrics, Stanford University;
2 Pediatric Stem Cell Transplantation, Stanford University, Palo
Alto, CA; 3 Stanford University School of Medicine, Palo Alto, CA;
4 Stanford University; 5 Pediatric Hematology/Oncology/BMT,
Rady Children's Hospital/Ucsd, San Diego, CA; 6 Dept. of
Pediatrics, Stanford University Medical Center, Stanford, CA;
7 Pediatric Stem Cell Transplant, Stanford University, Palo Alto,
CA
CMV disease in patients undergoing allogeneic HCT is
a major source of morbidity and mortality. CMV PCR allows
for earlier detection of viremia and preemptive anti-viral
therapy. A recent study by Milano et al. (Blood 2011) has
reported the efﬁcacy of the use of intensive CMV prophylaxis
in umbilical cord blood recipients. In this case series (table
below), we describe 3 patients in whom active CMV disease
was detected in the context of a viral load which ﬂuctuatedTable
Patient 1 Patient 2 Patient 3
Age/Sex 11/M 4/M 10/M
Underlying
Diagnosis
SAA with
secondary M7 AML
High risk
pre-B cell ALL
Relapsed
pre-B cell ALL
Donor
Source
Double umbilical
cord (dUCB)
9/10 matched
unrelated donor
dUCB
GVHD None Grade IV skin,
gut, and liver
GVHD
Grade III skin
and gut GVHD
CMV viral
load at
biopsy/
Range
<150 copies/ml
Not detected - <150
<150 copies/ml
Not detected -
<150
#1- 400
copies/ml, #2-
not detected
Not detected -
11,200
Disease Day +42
Esophagoduodenal
endoscopy: Gastritis
with CMV inclusions
and CMV positive
immunohistochemical
stain
Day +285
Cholecystectomy:
Perforated
chronic
cholecystitis
with hemobilia,
CMV PCR pos
Day +162
Left endoscopic
sphenoidotomy:
Chronic
inﬂammation
with shell vial
CMV positivity
Day +286 Lung
biopsy: CMV
PCR pos
Outcome Symptoms of gastritis
resolved
Gradual but
complete
recovery after
stabilization in
the
ICU
Symptoms
improved,
Follow up CT
scans showed
improvementbetween very low level viremia (<150 copies/ml) and
undetectable. The patients (3 males, ages 4-11), all received
high risk transplants (2 double cord, 1 9/10 URD) for
advanced leukemias. All three received myeloablative doses
of total body irradiation and cyclophosphamide and the two
cord blood recipients received ﬂudarabine additionally. All
patients were CMV sero-positive while their donors were
CMV sero-negative. They had symptomatic biopsy-proven
CMV disease in various locations including the stomach,
gallbladder, sinuses and lung. They were treated with intra-
venous ganciclovir and Cytogam induction and two transi-
tioned to foscarnet due to myelosuppression. All three
recovered from their symptomatic disease, although they
continued to have ﬂuctuating positivity of their serum CMV
PCR. This experience at a single institution in the last year
suggests that although CMV PCR has reduced the need for
prophylactic ganciclovir in patients undergoing allogeneic
HCT, active infection can develop in high risk patients even
with very low level of viremia. Therefore, an intensive
prophylactic strategy and treatment of any level of viremia,
along with a high index of suspicion for CMV disease is
required in high risk patients. Additionally, tissue diagnosis,
especially with unusual organ involvement such as gall-
bladder in our patient, should be obtained when possible.408
Sequential Allogeneic Stem Cell Transplantation in High
Risk Acute Myeloid Leukemia and Myelodysplastic
Syndrome
Alzbeta Zavrelova, Jakub Radocha, Miriam Lanska, Pavel Zak.
Faculty Hospital Hradec Kralove, IV. department of internal
medicine - hematology, Czech Republic
Aim: To evaluate this strategy in high risk acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS).
We treated 17 patients with AML or MDS. This cohort
consisted of nine patients who did not reach complete
remission, 5 patients who reached complete remission but
remainedwith high burden of residual disease and 3 patients
up front transplanted for myelodysplatic syndrome with
high blast count. Median age was 54 years (32-65years).
Median count of blasts in bone marrow before sequential
transplantationwas 9% (1-76%). 6 patients were transplanted
with HLA identical sibling, 8 patients were transplanted with
matched unrelated donor (10/10) and 3 patients had unre-
lated donor with one mismatch (9/10). Flag-Ida chemo-
therapy (CHT) (n¼4), 3+7 CHT (n¼7) or CHT based on
monotherapy with Cytarabin was used as a cytoreduction.
Between cytoreductive CHT and preparative regimen was
instituted rest period with median of 5 days (2-14 days).
After these days of rest preparative regimen consisted of
Fludarabin/Busulfan was initiated. Total dose o Busulfan was
8mg/kg n¼6), 12mg/kg(n¼6) nad 16mg/kg (n¼5). Thymo-
globulin (total dose 7,5mg/kg) was used in case of unrelated
donor in days -3 to -1.
Results: Estimated overall survival at 2 years was 67,6%.
Whole regimen was tolerated very well even with the
highest dose of Busulfan. Transplant related mortality at 100
days was 6% (1 patient with insuﬁtient engraftment died due
to infection). 5 patients relapsed after transplantation, 1
patient progressed after transplantation. From these patients
just 1 patient did not die due to relapse and was succesfully
rescued with chemotherapy and donor lymphocyte infusion.
Conclusion: Sequential transplantation is our method of
choice in high risk AML and MDS. We demonstrate very low
transplant related mortality and promising long term
survival of this cohort of high risk patients.
